<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709289</url>
  </required_header>
  <id_info>
    <org_study_id>2020-04</org_study_id>
    <nct_id>NCT04709289</nct_id>
  </id_info>
  <brief_title>Adverse Effects of ALA-PDT for the Treatment of Moderate to Severe Acne Vulgaris: a Prospective Study</brief_title>
  <official_title>Adverse Effects of ALA-PDT for the Treatment of Moderate to Severe Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Dermatology Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Dermatology Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand, prevent and treat the adverse reactions more comprehensively, we sought to&#xD;
      systemically document the adverse effects of ALA-PDT for moderate to severe acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To understand, prevent and treat the adverse reactions more comprehensively, we sought to&#xD;
      systemically document the adverse effects of ALA-PDT for moderate to severe acne vulgaris.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Evaluator assesses photographs without prior knowledge of intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The clearance rate of lesions</measure>
    <time_frame>1 week after treatment</time_frame>
    <description>The change rate in lesion clearance of acne vulgaris at 7 days after treatment will be measured as the primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse effects</measure>
    <time_frame>up to 7 days after treatment.</time_frame>
    <description>the incidence, severity, occurrence and duration time of erythema, pain, burning skin, itching, pustule, exudation, edema, blister, dry skin, crust and hyperpigmentation of last treatment, as well as lesion photos were detailed asked and recorded during the clinical encounter, up to 7 days after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Conventional Photodynamic Therapy(C-PDT) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aminolevulinic acid, photodynamic therapy</intervention_name>
    <description>Aminolevulinic acid, photodynamic therapy</description>
    <arm_group_label>Conventional Photodynamic Therapy(C-PDT) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Patients diagnosed with moderate to severe acne and graded grade III-IV according&#xD;
             to Investigator's Global Assessment (IGA) ;&#xD;
&#xD;
          -  (2) Patients unsuitable for drug treatment owing to various reasons and who&#xD;
             voluntarily participated and signed informed consent following information about other&#xD;
             alternatives;&#xD;
&#xD;
          -  (3) Patients who read the instructions and were willing to follow the program&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Patients who had a history of photosensitive diseases;&#xD;
&#xD;
          -  (2) Patients who had Modified-PDT;&#xD;
&#xD;
          -  (3) Patients who had oral isotretinoin in the past 3 months, used oral contraceptives&#xD;
             or antibiotics and underwent local or facial surgery in the past 4 weeks;&#xD;
&#xD;
          -  (4) Female patients who were pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Wang, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Skin Disease Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lei Shi</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Dermatology Hospital</investigator_affiliation>
    <investigator_full_name>Xiuli Wang</investigator_full_name>
    <investigator_title>Director, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

